Identifying and treating patients with suboptimal responses

Bruce A. Cohen, O. Khan, D. R. Jeffery, K. Bashir, S. A. Rizvi, E. J. Fox, M. Agius, R. Bashir, T. E. Collins, R. Herndon, P. Kinkel, D. D. Mikol, M. A. Picone, V. Rivera, C. Tornatore, H. Zwibel

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Multiple sclerosis (MS) is an immune-mediated neurologic disease in which acute inflammatory events early in the disease course contribute to subsequent neurologic disability. The early relapsing inflammatory phase is followed by a progressive degenerative phase in which the frequency of acute inflammatory attacks diminishes but progressive loss of neurologic function continues. Current immune therapies are most effective in suppressing the acute inflammatory events that characterize the earlier stages of disease. Optimal suppression of these inflammatory events is likely to have the best potential for delaying or preventing loss of axons and decline in neurologic function. In view of these considerations, and because MS is a heterogeneous disease and response to disease-modifying agents (DMA) varies across individuals, it is important to identify suboptimal responders as early as possible to allow therapeutic modification while the opportunity to avert future loss of function remains. At present, no criteria for identifying suboptimal responders have been validated. In January 2004, a group of neurologists from 16 MS centers in the United States met to develop a consensus on criteria for defining suboptimal response for use in compelling clinical situations and to prompt clinical studies to validate the efficacy of these criteria. Consensus criteria included relapse rates of either 1/year or unchanged from pretreatment rates, incomplete recovery from multiple attacks, evolution of polyregional neurologic involvement, recurrent brainstem or spinal cord lesions, and cumulative loss of neurologic function sufficient to disrupt daily activities. The panel then considered the use of mitoxantrone for patients with worsening MS and a suboptimal response to DMA therapy.

Original languageEnglish (US)
JournalNeurology
Volume63
Issue number12 SUPPL. 6
StatePublished - Dec 28 2004

Fingerprint

Nervous System
Multiple Sclerosis
Mitoxantrone
Nervous System Diseases
Brain Stem
Axons
Spinal Cord
Therapeutics
Recurrence

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Cohen, B. A., Khan, O., Jeffery, D. R., Bashir, K., Rizvi, S. A., Fox, E. J., ... Zwibel, H. (2004). Identifying and treating patients with suboptimal responses. Neurology, 63(12 SUPPL. 6).

Identifying and treating patients with suboptimal responses. / Cohen, Bruce A.; Khan, O.; Jeffery, D. R.; Bashir, K.; Rizvi, S. A.; Fox, E. J.; Agius, M.; Bashir, R.; Collins, T. E.; Herndon, R.; Kinkel, P.; Mikol, D. D.; Picone, M. A.; Rivera, V.; Tornatore, C.; Zwibel, H.

In: Neurology, Vol. 63, No. 12 SUPPL. 6, 28.12.2004.

Research output: Contribution to journalArticle

Cohen, BA, Khan, O, Jeffery, DR, Bashir, K, Rizvi, SA, Fox, EJ, Agius, M, Bashir, R, Collins, TE, Herndon, R, Kinkel, P, Mikol, DD, Picone, MA, Rivera, V, Tornatore, C & Zwibel, H 2004, 'Identifying and treating patients with suboptimal responses', Neurology, vol. 63, no. 12 SUPPL. 6.
Cohen BA, Khan O, Jeffery DR, Bashir K, Rizvi SA, Fox EJ et al. Identifying and treating patients with suboptimal responses. Neurology. 2004 Dec 28;63(12 SUPPL. 6).
Cohen, Bruce A. ; Khan, O. ; Jeffery, D. R. ; Bashir, K. ; Rizvi, S. A. ; Fox, E. J. ; Agius, M. ; Bashir, R. ; Collins, T. E. ; Herndon, R. ; Kinkel, P. ; Mikol, D. D. ; Picone, M. A. ; Rivera, V. ; Tornatore, C. ; Zwibel, H. / Identifying and treating patients with suboptimal responses. In: Neurology. 2004 ; Vol. 63, No. 12 SUPPL. 6.
@article{2361db2f9a9e474a9365712460db963d,
title = "Identifying and treating patients with suboptimal responses",
abstract = "Multiple sclerosis (MS) is an immune-mediated neurologic disease in which acute inflammatory events early in the disease course contribute to subsequent neurologic disability. The early relapsing inflammatory phase is followed by a progressive degenerative phase in which the frequency of acute inflammatory attacks diminishes but progressive loss of neurologic function continues. Current immune therapies are most effective in suppressing the acute inflammatory events that characterize the earlier stages of disease. Optimal suppression of these inflammatory events is likely to have the best potential for delaying or preventing loss of axons and decline in neurologic function. In view of these considerations, and because MS is a heterogeneous disease and response to disease-modifying agents (DMA) varies across individuals, it is important to identify suboptimal responders as early as possible to allow therapeutic modification while the opportunity to avert future loss of function remains. At present, no criteria for identifying suboptimal responders have been validated. In January 2004, a group of neurologists from 16 MS centers in the United States met to develop a consensus on criteria for defining suboptimal response for use in compelling clinical situations and to prompt clinical studies to validate the efficacy of these criteria. Consensus criteria included relapse rates of either 1/year or unchanged from pretreatment rates, incomplete recovery from multiple attacks, evolution of polyregional neurologic involvement, recurrent brainstem or spinal cord lesions, and cumulative loss of neurologic function sufficient to disrupt daily activities. The panel then considered the use of mitoxantrone for patients with worsening MS and a suboptimal response to DMA therapy.",
author = "Cohen, {Bruce A.} and O. Khan and Jeffery, {D. R.} and K. Bashir and Rizvi, {S. A.} and Fox, {E. J.} and M. Agius and R. Bashir and Collins, {T. E.} and R. Herndon and P. Kinkel and Mikol, {D. D.} and Picone, {M. A.} and V. Rivera and C. Tornatore and H. Zwibel",
year = "2004",
month = "12",
day = "28",
language = "English (US)",
volume = "63",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "12 SUPPL. 6",

}

TY - JOUR

T1 - Identifying and treating patients with suboptimal responses

AU - Cohen, Bruce A.

AU - Khan, O.

AU - Jeffery, D. R.

AU - Bashir, K.

AU - Rizvi, S. A.

AU - Fox, E. J.

AU - Agius, M.

AU - Bashir, R.

AU - Collins, T. E.

AU - Herndon, R.

AU - Kinkel, P.

AU - Mikol, D. D.

AU - Picone, M. A.

AU - Rivera, V.

AU - Tornatore, C.

AU - Zwibel, H.

PY - 2004/12/28

Y1 - 2004/12/28

N2 - Multiple sclerosis (MS) is an immune-mediated neurologic disease in which acute inflammatory events early in the disease course contribute to subsequent neurologic disability. The early relapsing inflammatory phase is followed by a progressive degenerative phase in which the frequency of acute inflammatory attacks diminishes but progressive loss of neurologic function continues. Current immune therapies are most effective in suppressing the acute inflammatory events that characterize the earlier stages of disease. Optimal suppression of these inflammatory events is likely to have the best potential for delaying or preventing loss of axons and decline in neurologic function. In view of these considerations, and because MS is a heterogeneous disease and response to disease-modifying agents (DMA) varies across individuals, it is important to identify suboptimal responders as early as possible to allow therapeutic modification while the opportunity to avert future loss of function remains. At present, no criteria for identifying suboptimal responders have been validated. In January 2004, a group of neurologists from 16 MS centers in the United States met to develop a consensus on criteria for defining suboptimal response for use in compelling clinical situations and to prompt clinical studies to validate the efficacy of these criteria. Consensus criteria included relapse rates of either 1/year or unchanged from pretreatment rates, incomplete recovery from multiple attacks, evolution of polyregional neurologic involvement, recurrent brainstem or spinal cord lesions, and cumulative loss of neurologic function sufficient to disrupt daily activities. The panel then considered the use of mitoxantrone for patients with worsening MS and a suboptimal response to DMA therapy.

AB - Multiple sclerosis (MS) is an immune-mediated neurologic disease in which acute inflammatory events early in the disease course contribute to subsequent neurologic disability. The early relapsing inflammatory phase is followed by a progressive degenerative phase in which the frequency of acute inflammatory attacks diminishes but progressive loss of neurologic function continues. Current immune therapies are most effective in suppressing the acute inflammatory events that characterize the earlier stages of disease. Optimal suppression of these inflammatory events is likely to have the best potential for delaying or preventing loss of axons and decline in neurologic function. In view of these considerations, and because MS is a heterogeneous disease and response to disease-modifying agents (DMA) varies across individuals, it is important to identify suboptimal responders as early as possible to allow therapeutic modification while the opportunity to avert future loss of function remains. At present, no criteria for identifying suboptimal responders have been validated. In January 2004, a group of neurologists from 16 MS centers in the United States met to develop a consensus on criteria for defining suboptimal response for use in compelling clinical situations and to prompt clinical studies to validate the efficacy of these criteria. Consensus criteria included relapse rates of either 1/year or unchanged from pretreatment rates, incomplete recovery from multiple attacks, evolution of polyregional neurologic involvement, recurrent brainstem or spinal cord lesions, and cumulative loss of neurologic function sufficient to disrupt daily activities. The panel then considered the use of mitoxantrone for patients with worsening MS and a suboptimal response to DMA therapy.

UR - http://www.scopus.com/inward/record.url?scp=19944415573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944415573&partnerID=8YFLogxK

M3 - Article

C2 - 15623669

AN - SCOPUS:19944415573

VL - 63

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 12 SUPPL. 6

ER -